Azathioprine + cyclophosphamide
Azathioprine + cyclophosphamide has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Mar 16, 2026: “Efficacy and safety of supportive and immunosuppressive therapies in the treatment of lgA nephropathy: a network Meta-analysis of randomized clinical…”.
1 new paper in 30 daysSee all 4 papers on azathioprine + cyclophosphamide
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
What did studies of azathioprine + cyclophosphamide find?
1Studies of azathioprine + cyclophosphamide measured one outcome, 24-hour proteinuria.
24-hour proteinuria
downin humans1
1 study
24-hour proteinuria
downin humans1
Azathioprine + cyclophosphamide decreases 24-hour proteinuria in humans (SUCRA 95.8%).
“AZA+CTX was associated with an effective reduction in 24-hour proteinuria in small RCTs”
Review
BMC nephrology
What is azathioprine + cyclophosphamide linked with?
1Studies link azathioprine + cyclophosphamide with renal failure progression.
Renal failure progression
upin humans1
1 study
Renal failure progression
upin humans1
Azathioprine + cyclophosphamide raises the risk of renal failure progression in humans.
“but it also increased the risk of renal failure progression and had poor safety”
Review
BMC nephrology